Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More General business news Dar Al-Handasah Consultants secures new framework agreement with Aramco Dar Al-Handasah Consultants, also known as Shair and Partners and a part of Sidara, has announced a significant… byPallavi MadhirajuJuly 21, 2024